1. Oncotarget. 2017 Oct 30;8(65):108786-108801. doi: 10.18632/oncotarget.22150. 
eCollection 2017 Dec 12.

Transcriptional response to hypoxic stress in melanoma and prognostic potential 
of GBE1 and BNIP3.

Buart S(1), Terry S(1), Noman MZ(1), Lanoy E(2), Boutros C(3), Fogel P(4), 
Dessen P(5), Meurice G(5), Gaston-Mathé Y(6), Vielh P(7), Roy S(3), Routier 
E(3), Marty V(7), Ferlicot S(8), Legrès L(9), Bouchtaoui ME(9), Kamsu-Kom N(10), 
Muret J(1), Deutsch E(11)(12)(13)(14), Eggermont A(3)(14), Soria JC(10)(12), 
Robert C(3)(10)(14), Chouaib S(1).

Author information:
(1)INSERM UMR1186, Integrative Tumor Immunology and Genetic Oncology, Gustave 
Roussy, Equipe Labellisée par La Ligue Contre Le Cancer, EPHE, Faculté de 
Médecine, Université Paris-Sud, Université Paris-Saclay, Villejuif, France.
(2)INSERM UMR 1018, Gustave Roussy, Université Paris-Sud, Université 
Paris-Saclay, Villejuif, France.
(3)Department of Medical Oncology, Gustave Roussy, Villejuif, France.
(4)Independent Consultant, Paris, France.
(5)Plateforme de Bioinformatique, UMS AMMICA, Gustave Roussy, Villejuif, France.
(6)YGM Consult, CEO, Paris, France.
(7)Département de Biologie et Pathologie Médicales, Gustave Roussy, Villejuif, 
France.
(8)Service d'Anatomie Pathologique, Hôpitaux Universitaires Paris Sud, AP-HP, Le 
Kremlin Bicêtre, France.
(9)Laboratoire de Pathologie, INSERM UMR_S-1165/Université Paris-Diderot, 
Sorbonne Paris Cité, Paris, France.
(10)INSERM UMR 981, Gustave Roussy, Université Paris-Sud, Université 
Paris-Saclay, Villejuif, France.
(11)Department of Radiation Oncology, Gustave Roussy, Villejuif, France.
(12)Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.
(13)INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Sud, 
Université Paris-Saclay, Villejuif, France.
(14)Faculty of Medicine, Université Paris-Sud, Université Paris-Saclay, Le 
Kremlin-Bicêtre, France.

Gradients of hypoxia occur in most solid tumors and cells found in hypoxic 
regions are associated with the most aggressive and therapy-resistant fractions 
of the tumor. Despite the ubiquity and importance of hypoxia responses, little 
is known about the variation in the global transcriptional response to hypoxia 
in melanoma. Using microarray technology, whole genome gene expression profiling 
was first performed on established melanoma cell lines. From gene set enrichment 
analyses, we derived a robust 35 probes signature (hypomel for HYPOxia MELanoma) 
associated with hypoxia-response pathways, including 26 genes up regulated, and 
9 genes down regulated. The microarray data were validated by RT-qPCR for the 35 
transcripts. We then validated the signature in hypoxic zones from 8 patient 
specimens using laser microdissection or macrodissection of Formalin 
fixed-paraffin-embedded (FFPE) material, followed with RT-qPCR. Moreover, a 
similar hypoxia-associated gene expression profile was observed using NanoString 
technology to analyze RNAs from FFPE melanoma tissues of a cohort of 19 patients 
treated with anti-PD1. Analysis of NanoString data from validation sets using 
Non-Negative Matrix Factorization (NMF) analysis (26 genes up regulated in 
hypoxia) and dual clustering (samples and genes) further revealed that the 
increased level of BNIP3 (Bcl-2 adenovirus E1B 19 kDa-interacting protein 
3)/GBE1 (glycogen branching enzyme1) differential pair correlates with the lack 
of response of melanoma patients to anti-PD1 (pembrolizumab) immunotherapy. 
These studies suggest that through elevated glycogenic flux and induction of 
autophagy, hypoxia is a critical molecular program that could be considered as a 
prognostic factor for melanoma.

DOI: 10.18632/oncotarget.22150
PMCID: PMC5752481
PMID: 29312568

Conflict of interest statement: CONFLICTS OF INTEREST We declare no competing 
financial interests.